Major trial tests promising new drug cocktail for Tough-to-Treat stomach cancer
NCT ID NCT07315750
Summary
This large, late-stage study is comparing a new three-drug combination against current standard treatments for advanced stomach cancer that has a specific biological marker (HER2-high). It aims to see if the new approach can better control the cancer and help people live longer. The trial is for adults who have not yet received treatment for their advanced cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, BJ-Beijing, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.